Novel human protein C derivatives are described. These derivatives have
increased anti-coagulation activity and resistance to inactivation by
serpins, compared to wild-type protein C and retain the biological
activity of the wild-type human protein D. These derivatives will require
either less frequent administration and/or smaller dosage than wild-type
human protein C in the treatment of acute coronary syndromes, vascular
occlusive disorders, hyper coagulable states, thrombotic disorders and
disease states predisposing to thrombosis.
